Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ESTA
ESTA logo

ESTA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
90.480
Open
90.480
VWAP
89.21
Vol
440.06K
Mkt Cap
2.63B
Low
87.900
Amount
39.26M
EV/EBITDA(TTM)
--
Total Shares
29.43M
EV
2.82B
EV/OCF(TTM)
--
P/S(TTM)
11.50
Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.
Show More

Events Timeline

(ET)
2026-06-29
08:30:00
Establishment Labs Appoints Taylor Harris to Board of Directors
select
2026-05-06 (ET)
2026-05-06
08:10:00
Company Reports Q1 Revenue of $59.9M, Exceeding Expectations
select
2026-05-06
08:10:00
Company Expects Minimally Invasive Business to Exceed $35M in 2026
select
2026-04-30 (ET)
2026-04-30
09:00:00
Establishment Labs Secures $300M Loan Facility
select
2026-04-17 (ET)
2026-04-17
16:00:00
Asana Short Interest Soars to 33%
select
2026-04-07 (ET)
2026-04-07
08:10:00
Establishment Labs Surpasses 5 Million Motiva Devices
select

News

Newsfilter
8.5
06-25Newsfilter
Conexeu Sciences Targets GLP-1 Aesthetics Market with Innovative Platform
  • Market Validation: Galderma's presentation of clinical data on its injectables (Sculptra, Restylane) addressing medication-induced facial volume loss signifies that the 'Ozempic face' category has gained formal recognition, catalyzing rapid growth in the aesthetics industry.
  • Surge in Patient Demand: In 2024, U.S. plastic surgeons treated over 837,000 GLP-1 patients, indicating a swift rise in demand for facial restoration, which highlights the substantial potential and business opportunities within this emerging market.
  • Technological Innovation: Conexeu's CXU™ platform features a thermosensitive collagen scaffold designed for tissue regeneration rather than mere filling, with a targeted FDA 510(k) submission planned for early 2027, which could open new market avenues for the company if successful.
  • Competitive Landscape: As a newly public entity, Conexeu faces competition from established players like Galderma, yet its unique regenerative technology may allow it to carve out a niche in the rapidly expanding aesthetics market.
seekingalpha
8.5
06-25seekingalpha
Establishment Labs to Join Russell 2000 Index
  • Inclusion in Russell 2000: Establishment Labs (ESTA) will be added to the US small-cap Russell 2000 Index as part of the 2026 Russell indexes reconstitution, effective June 29, 2026, which is expected to enhance the company's market visibility and attract investor interest.
  • Revenue Forecast Increase: The company targets a revenue range of $266.5 million to $268.5 million for 2026, reflecting a rise in minimally invasive revenue forecasts exceeding $35 million, indicating strong growth potential in the medical device market.
  • Quant Rating Improvement: Seeking Alpha's Quant Rating highlights Establishment Labs as a strong performer in foreign healthcare, further boosting investor confidence and potentially attracting more institutional investors to the stock.
  • Historical Earnings Data: The historical earnings data for Establishment Labs provides crucial financial context for investors, aiding in the assessment of the company's long-term growth potential and market performance, which will play a key role in future investment decisions.
PRnewswire
8.5
06-16PRnewswire
Conexeu Sciences Expands Board to Support Commercialization Efforts
  • Board Expansion: On June 15, 2026, Conexeu Sciences Inc. expanded its board from six to nine members, with new directors primarily from Fortune 500 companies, signaling the company's ambition to transition its cutting-edge tissue regeneration technology into a viable business.
  • Executive Appointment: Co-founder David Bogart was promoted to Chief Commercial Officer, overseeing over $75 million in capital formation, indicating Conexeu's focus on commercial strategy and market outreach to lay the groundwork for future growth.
  • Technology Platform: Conexeu's CXU™ platform is a bioregenerative extracellular matrix that rapidly transitions into a stable gel scaffold at body temperature, expected to target multiple billion-dollar markets including advanced wound care and medical aesthetics, showcasing its broad market potential.
  • Market Outlook: With an aging population and the diabetes epidemic, the field of tissue regeneration is experiencing strong market momentum, and while Conexeu faces challenges from larger competitors, its unique technology and leadership team position it well for future success.
Fool
6.5
05-30Fool
Rice Hall James Reduces Stake in Establishment Labs
  • Share Reduction Transaction: Rice Hall James & Associates sold 102,885 shares of Establishment Labs in Q1 2026, valued at approximately $7.03 million, indicating a cautious outlook on the company's future growth potential.
  • Holding Proportion Change: Following the sale, Rice Hall James's stake in Establishment Labs decreased to 548,674 shares, representing 1.73% of its reportable assets under management, reflecting a diminished confidence in the stock.
  • Company Financial Overview: As of May 14, 2026, Establishment Labs' stock price was $69.80, up 91.4% over the past year, despite a net loss of $43.74 million, indicating strong market demand and revenue growth.
  • Investor Risk Advisory: While Establishment Labs is experiencing rapid growth in the aesthetic surgery market, it faces cash flow pressures and regulatory challenges, making it suitable for growth-oriented investors willing to accept volatility, while conservative investors may find it unsuitable.
NASDAQ.COM
2.0
05-30NASDAQ.COM
Rice Hall James Sells ESTA Shares Worth $7.03 Million
  • Share Sale Details: On May 15, 2026, Rice Hall James & Associates sold 102,885 shares of Establishment Labs (NASDAQ:ESTA) for an estimated $7.03 million, reflecting the fund's strategy to reduce its position during the first quarter.
  • Quarter-End Position Value: At quarter-end, the fund held 548,674 shares of ESTA valued at $31.15 million, indicating that despite the reduction, ESTA still represents 1.73% of the fund's total assets under management.
  • Market Performance Analysis: Establishment Labs' stock surged approximately 100% over the past year, and this sale appears to be profit-taking, reflecting investors' balancing of confidence in future growth against inherent risks.
  • Investor Risk Advisory: While Establishment Labs is rapidly growing in the aesthetic surgery market, it remains unprofitable and faces cash burn and regulatory pressures, making it suitable for growth-oriented investors who can tolerate volatility.
Globenewswire
8.5
05-22Globenewswire
Conexeu Sciences Inc. Goes Public, Pioneering a New Era in Regenerative Medicine
  • IPO Milestone: Conexeu Sciences Inc. successfully debuted on Nasdaq on May 21, 2026, with 25,269,996 shares outstanding and a fully diluted total of 35,238,222 shares, marking a significant advancement in regenerative medicine and enhancing its market competitiveness.
  • Innovative Product Launch: The company unveiled its 3D bioprinted regenerative breast matrix, B.R.E.A.S.T.™, designed to provide a temporary scaffold for patients post-mastectomy, targeting over 100,000 women annually who opt out of reconstruction, thus opening a larger market opportunity.
  • Platform Advantage: Conexeu's CXU™ platform can be applied across multiple tissue regeneration products, streamlining product development processes and targeting multi-billion-dollar markets in wound care, periodontal applications, and facial contouring, indicating vast market potential.
  • Regulatory Strategy: The company plans to submit a 510(k) application in early 2027, transitioning its products from investigational to commercial status, further solidifying its leadership position in the regenerative medicine sector.
Wall Street analysts forecast ESTA stock price to rise
8 Analyst Rating
Wall Street analysts forecast ESTA stock price to rise
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
75.00
Averages
82.88
High
90.00
Current: 0.000
sliders
Low
75.00
Averages
82.88
High
90.00
BTIG
Buy
maintain
$88 -> $90
AI Analysis
2026-05-07
Reason
BTIG
Price Target
$88 -> $90
AI Analysis
2026-05-07
maintain
Buy
Reason
BTIG raised the firm's price target on Establishment Labs to $90 from $88 and keeps a Buy rating on the shares. The company's results were driven by continued U.S. Motiva outperformance, with revenue of $19.6M representing 13% sequential growth despite the seasonally softer quarter, and momentum has carried into Q2 with the company setting new weekly order highs, the analyst tells investors in a research note.
Citi
Joanne Wuensch
Neutral
maintain
$65 -> $76
2026-05-06
Reason
Citi
Joanne Wuensch
Price Target
$65 -> $76
2026-05-06
maintain
Neutral
Reason
Citi analyst Joanne Wuensch raised the firm's price target on Establishment Labs to $76 from $65 and keeps a Neutral rating on the shares. The firm says this was "a straightforward quarter," with a modest guidance raise as management ramps the pipeline. It seems that the U.S. Motiva launch and global Preserve launch are progressing in line or exceeding expectations, with the relatively benign guidance raise likely a reflection of conservatism, Citi adds. Still, with several launches still nascent and an uncertain global economy, the firm stays on the sidelines.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ESTA
Unlock Now

Valuation Metrics

The current forward P/E ratio for Establishment Labs Holdings Inc (ESTA.O) is 0.00, compared to its 5-year average forward P/E of -30.16. For a more detailed relative valuation and DCF analysis to assess Establishment Labs Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-30.16
Current PE
0.00
Overvalued PE
-13.55
Undervalued PE
-46.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-85.35
Current EV/EBITDA
-90.11
Overvalued EV/EBITDA
41.86
Undervalued EV/EBITDA
-212.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
7.35
Current PS
7.79
Overvalued PS
9.56
Undervalued PS
5.13

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stocks to pick right now for day trading
Intellectia · 820 candidates
Region: USPrice: >= $5.00Volume: >= 0Rsi Category: moderatePrice Change Pct: >= $0.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceCrossAboveMA5, PriceCrossAboveMA20Min5 Price Change Pct: >= $0.00Intraday Amplitude: >= 0
Ticker
Name
Market Cap$
top bottom
ERNA logo
ERNA
Ernexa Therapeutics Inc
4.65M
SIM logo
SIM
Grupo Simec SAB de CV
4.30B
STRC logo
STRC
Strategy Inc
65.56B
BRID logo
BRID
Bridgford Foods Corp
67.62M
NVAX logo
NVAX
Novavax Inc
1.33B
SLP logo
SLP
Simulations Plus Inc
317.43M
Daytrading Signale andern
Intellectia · 28 candidates
Price: $5.00 - $100.00Relative Vol: >= 1.80Moving Average Relationship: PriceAboveMA20Three Min Rate Of Change: >= 0.7%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ONDS logo
ONDS
Ondas Inc
4.53B
VG logo
VG
Venture Global Inc
27.96B
SOUN logo
SOUN
SoundHound AI Inc
3.63B
VIAV logo
VIAV
Viavi Solutions Inc
8.18B
NTLA logo
NTLA
Intellia Therapeutics Inc
1.82B
LION logo
LION
Lionsgate Studios Corp
2.61B
create a small cap screener
Intellectia · 1387 candidates
Market Cap Category: small
Ticker
Name
Market Cap$
top bottom
SGRY logo
SGRY
Surgery Partners Inc
2.00B
QDEL logo
QDEL
QuidelOrtho Corp
2.00B
NESR logo
NESR
National Energy Services Reunited Corp
2.00B
DXPE logo
DXPE
DXP Enterprises Inc
2.00B
SKWD logo
SKWD
Skyward Specialty Insurance Group Inc
2.00B
NTCT logo
NTCT
Netscout Systems Inc
2.00B
low cap stocks with a bullish cross
Intellectia · 1029 candidates
Market Cap Category: small, micro, nanoMoving Average Relationship: PriceCrossAboveMA5
Ticker
Name
Market Cap$
top bottom
NTCT logo
NTCT
Netscout Systems Inc
2.00B
NESR logo
NESR
National Energy Services Reunited Corp
2.00B
FMC logo
FMC
FMC Corp
1.99B
VECO logo
VECO
Veeco Instruments Inc
1.99B
CMPR logo
CMPR
Cimpress PLC
1.98B
STC logo
STC
Stewart Information Services Corp
1.98B
what about health tech stocks and robots?
Intellectia · 18 candidates
Market Cap: 50.00M - 50.00BWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ROK logo
ROK
Rockwell Automation Inc
47.26B
SYM logo
SYM
Symbotic Inc
36.98B
TER logo
TER
Teradyne Inc
36.32B
VEEV logo
VEEV
Veeva Systems Inc
36.12B
ZBRA logo
ZBRA
Zebra Technologies Corp
12.31B
DOCS logo
DOCS
Doximity Inc
7.50B

Whales Holding ESTA

S
Summit Partners Public Asset Management, LLC
Holding
ESTA
+43.34%
3M Return
R
Redmile Group, LLC
Holding
ESTA
+20.64%
3M Return
B
Boothbay Fund Management, LLC
Holding
ESTA
+18.63%
3M Return
S
Sofinnova Investments, Inc.
Holding
ESTA
+17.85%
3M Return
N
Nantahala Capital Management, LLC
Holding
ESTA
+16.04%
3M Return
D
Discovery Capital Management, LLC
Holding
ESTA
+14.98%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Establishment Labs Holdings Inc (ESTA) stock price today?

The current price of ESTA is 89.25 USD — it has increased 0.02

What is Establishment Labs Holdings Inc (ESTA)'s business?

Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.

What is the price predicton of ESTA Stock?

Wall Street analysts forecast ESTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESTA is82.88 USD with a low forecast of 75.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Establishment Labs Holdings Inc (ESTA)'s revenue for the last quarter?

Establishment Labs Holdings Inc revenue for the last quarter amounts to 59.88M USD, increased 44.71

What is Establishment Labs Holdings Inc (ESTA)'s earnings per share (EPS) for the last quarter?

Establishment Labs Holdings Inc. EPS for the last quarter amounts to -0.45 USD, decreased -35.71

How many employees does Establishment Labs Holdings Inc (ESTA). have?

Establishment Labs Holdings Inc (ESTA) has 1004 emplpoyees as of July 05 2026.

What is Establishment Labs Holdings Inc (ESTA) market cap?

Today ESTA has the market capitalization of 2.63B USD.